T1	Participants 59 120	previously untreated advanced esophagogastric cancer patients
T2	Participants 382 506	patients within an open label, randomized clinical phase II trial with advanced or metastatic gastric/esophagogastric cancer
T3	Participants 928 949	118 patients enrolled
